The role of the polymorphic efflux transporter P-glycoprotein on the brain accumulation of d-methylphenidate and d-amphetamine

Drug Metabolism and Disposition : the Biological Fate of Chemicals
Hao-Jie ZhuJohn S Markowitz

Abstract

The psychostimulant medications methylphenidate (MPH) and amphetamine (AMP), available in various ratios or enantiopure formulations of their respective active dextrorotary isomers, constitute the majority of agents used in the treatment of attention-deficit/hyperactivity disorder (ADHD). Substantial interindividual variability occurs in their pharmacokinetics and tolerability. Little is known regarding the potential role of drug transporters such as P-glycoprotein (P-gp) in psychostimulant pharmacokinetics and response. Therefore, experiments were carried out in P-gp knockout (KO) mice versus wild-type (WT) mice after intraperitoneal dosing (2.5 mg/kg) of d-MPH or (3.0 mg/kg) of d-AMP. After the administration of each psychostimulant, locomotor activity was assessed at 30-min intervals for 2 h. Total brain-to-plasma drug concentration ratios were determined at 10-, 30-, and 80-min postdosing time-points. The results showed no statistically supported genotypic difference in d-AMP-induced locomotor activity stimulation or in brain-to-plasma ratio of d-AMP. As for d-MPH, the P-gp KO mice had 33% higher brain concentrations (p < 0.05) and 67.5% higher brain-to-plasma ratios (p < 0.01) than WT controls at the 10-min postdosing time...Continue Reading

References

May 7, 1999·Journal of the American Academy of Child and Adolescent Psychiatry·L L GreenhillH Abikoff
May 20, 1999·Annual Review of Pharmacology and Toxicology·S V AmbudkarM M Gottesman
May 10, 2000·Journal of the American Academy of Child and Adolescent Psychiatry·S R PliszkaS K Wynne
Jun 6, 2000·Advanced Drug Delivery Reviews·A H Schinkel
Oct 3, 2001·Pediatrics·UNKNOWN American Academy of Pediatrics. Subcommittee on Attention-Deficit/Hyperactivity Disorder and Committee on Quality Improvemen
Feb 9, 2002·Journal of the American Academy of Child and Adolescent Psychiatry·Laurence L GreenhillUNKNOWN American Academy of Child and Adolescent Psychiatry
Sep 28, 2002·Journal of Clinical Psychopharmacology·Stephen V FaraoneChristine Roe
Dec 20, 2002·Clinical Pharmacokinetics·Jiunn H Lin, Masayo Yamazaki
Jan 22, 2003·Advanced Drug Delivery Reviews·Jiunn H Lin
Apr 18, 2003·Journal of Medicinal Chemistry·Dietmar SchwabJörg Huwyler
Jan 1, 2004·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Jun-Sheng WangC Lindsay De Vane
Mar 6, 2004·Pharmacology·Gert Fricker, David S Miller
Oct 27, 2004·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Angela DoranChenghong Zhang
Mar 15, 2005·Toxicology Letters·David BalayssacFrançois Coudore
Jul 14, 2005·Progress in Neurobiology·Wolfgang Löscher, Heidrun Potschka
Jul 19, 2005·Lancet·Joseph Biederman, Stephen V Faraone
Sep 13, 2005·Clinical Pharmacology and Therapeutics·Richard H Ho, Richard B Kim
Nov 22, 2005·Expert Opinion on Drug Delivery·Kennerly S PatrickJohn S Markowitz

❮ Previous
Next ❯

Citations

Mar 5, 2011·Biological & Pharmaceutical Bulletin·Jillissa Christine MolnariAlan Lewis Myers
Jul 22, 2008·European Journal of Pharmacology·Andrew Crowe, Susanna Diep
May 9, 2014·American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics : the Official Publication of the International Society of Psychiatric Genetics·Estela Maria BruxelLuis Augusto Rohde
Apr 21, 2010·Journal of Neurochemistry·Hao-Jie ZhuJohn S Markowitz
Jan 21, 2014·Neuropharmacology·Joana GonçalvesAna Paula Silva
Nov 6, 2009·The International Journal of Neuropsychopharmacology·Nicolas TournierXavier Declèves
Apr 6, 2019·Pharmacogenetics and Genomics·Tyler StevensTeri E Klein
Sep 15, 2017·Journal of Child and Adolescent Psychopharmacology·John S Markowitz, Kennerly S Patrick

❮ Previous
Next ❯

Related Concepts

Related Feeds

Attention Disorders

Attention is involved in all cognitive activities, and attention disorders are reported in patients with various neurological diseases. Here are the latest discoveries pertaining to attention disorders.

Blood Brain Barrier

The blood brain barrier is a border that separates blood from cerebrospinal fluid. Discover the latest search on this highly selective semipermeable membrane here.

Blood Brain Barrier Chips

The blood brain barrier (BBB) is comprised of endothelial cells that regulate the influx and outflux of plasma concentrations. Lab-on-a-chip devices allow scientists to model diseases and mechanisms such as the passage of therapeutic antibodies across the BBB. Discover the latest research on BBB chips here.

Blood-Brain Barrier Transport in Neurodegeneration

The blood brain barrier is important for regulating the movement of biomolecules in and out of the brain. For example, membrane transporters in the blood brain barrier can be essential for regulating drug movement and dysregulation of these processes may play a role in neurodegeneration. This feed follows the latest research on this topic.

Related Papers

The Journal of Pharmacology and Experimental Therapeutics
Hao-Jie ZhuC Lindsay DeVane
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology
Hao-Jie ZhuC Lindsay DeVane
© 2022 Meta ULC. All rights reserved